App-Quantinova.ai

A PHASE II RANDOMISED CONTROLLED TRIAL OF ORAL PREDNISOLONE IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (PRedSS)

D. Griffiths-Jones - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

Prednisolone

A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY

X. Leng - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

A RANDOMISED CONTROLLED STUDY OF POLYACRYLAMIDE HYDROGEL VS. HYALURONIC ACID IN KNEE OSTEOARTHRITIS: RESULTS AT 12-MONTHS

H. Bliddal - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Hyaluronic acid

A REDUCTION IN NEW REFERRALS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND CRYSTAL ARTHRITIS COMPARED TO GCA DURING COVID19 PANDEMIC

M. Tormo-Ratera - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

A RETROSPECTIVE STUDY ON UVEITIS FLARES FOLLOWING COVID19 VACCINATION: SHARING EXPERIENCE FROM A TEACHING HOSPITAL COMBINED RHEUMATOLOGY AND UVEITIS CLINIC

A. Birchall - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Coronavirus disease

N/A

A review of the evidence behind the recommendation of rituximab for ANCA associated vasculitis

H. Amin - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Rituximab

A SYNTHESIS OF GUIDANCE AVAILABLE FOR ASSESSING METHODOLOGICAL QUALITY AND GRADING OF EVIDENCE FROM QUALITATIVE RESEARCH TO INFORM CLINICAL RECOMMENDATIONS: A SYSTEMATIC REVIEW

M. Sekhon - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY

P. Emery - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Abatacept

ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

R. Alten - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept

ADAPTING TO LIVING WITH AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS)

M. Garrido-Cumbrera - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

ADDRESSING THE VOCATIONAL DEVELOPMENT OF YOUNG PEOPLE WITH LONG-TERM HEALTH CONDITIONS IN HEALTH CARE SETTINGS: A SYSTEMATIC REVIEW AND MIXED METHODS SYNTHESIS

A. Farre - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

AN EPIDEMIOLOGICAL STUDY OF FOOT AND ANKLE PAIN AND HEALTH-RELATED JOB LOSS IN ADULTS OVER 50: CROSS-SECTIONAL FINDINGS FROM THE HEAF COHORT

D. Jobanputra - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Adalimumab

ANALYSIS OF WORLDWIDE RHEUMATOLOGY POSTGRADUATE TRAINING CURRICULA: A MAPPING EXERCISE TO INFORM THE DEVELOPMENT OF EULAR STANDARDS FOR THE TRAINING OF EUROPEAN RHEUMATOLOGISTS

A. Alunno - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

ANTI-CCP POSITIVE INDIVIDUALS AT RISK OF PROGRESSION TO INFLAMMATORY ARTHRITIS: WHAT HAPPENS TO BIOMARKERS PRIOR TO PROGRESSION?

L. Duquenne - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING

R. Alten - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept

ANTI-RITUXIMAB ANTIBODIES DEMONSTRATE NEUTRALISING CAPACITY, ASSOCIATE WITH LOWER CIRCULATING DRUG LEVELS AND EARLY RELAPSE IN PATIENTS UNDERGOING TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS

C. Wincup - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Rituximab

ANTI-Sm AUTOANTIBODIES IDENTIFY A PHENOTYPE OF SEVERE SLE WITH AN ASSOCIATED SERUM BIOMARKER PROFILE

A. Hoi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

AORTIC MANIFESTATIONS IN GIANT CELL ARTERITIS: SINGLE CENTRE 10-YEAR EXPERIENCE

F. Coath - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Glucocorticoid

ARE BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ASSOCIATED WITH WORK PARTICIPATION IMPROVEMENT IN EARLY RHEUMATOID ARTHRITIS? A SYSTEMATIC REVIEW AND META-ANALYSIS

M. L. Marques - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filters

45280 Abstracts